Amyloid-β deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice

Journal of Neuropathology and Experimental Neurology

Volumn 63, Issue 5, 2004, Pages 418-428

  Sadowski, Marcin ^a   Pankiewicz, Joanna ^a   Scholtzova, Henrieta ^a   Ji, Yong ^a   Quartermain, David ^a   Jensen, Catrin H ^a   Duff, Karen ^b   Nixon, Ralph A ^a,b   Gruen, Rand J ^a   Wisniewsk, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Alzheimer disease; Amyloid ; Behavioral testing; Presenilin 1; Regional brain glucose metabolism; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; GENOTYPE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HIPPOCAMPUS; LEARNING; MAZE TEST; MEMORY DISORDER; MOUSE; NERVE CELL LESION; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; SPATIAL MEMORY; TRANSGENIC MOUSE; WORKING MEMORY;

EID: 2442664058     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/63.5.418     Document Type: Article

References (81)

1. De Santi S, De Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39
2. De Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[F-18]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-71
3. Silverman DHS, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia - Regional brain metabolism and long-term outcome. JAMA 2001;286:2120-27
4. Hsiao KK, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation and amyloid plaques in transgenic mice. Science 1996;274:99-102
5. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-27
6. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 1999;103:145-62
7. Wegiel J, Wisniewski HM, Kuchna I, et al. Cell-type-specific enhancement of amyloid-beta deposition in a novel presenilin-1 mutation (P117L). J Neuropathol Exp Neurol 1998;57:831-38
8. Gomez-Isla T, Growdon WB, McNamara MJ, et al. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain - Evidence for other phenotype-modifying factors. Brain 1999;122:1709-19
9. Holcomb L, Gordon MN, McGowan E, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Med 1998;4:97-100
10. Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-13
11. Wen PH, Shao X, Shao Z, et al. Overexpression of wild type but not an FAD mutant presenilin-1 promotes hippocampal neurogenesis in adult mice. Neurobiol Dis (in press)
12. Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JE. Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 2000;101:939-44
13. McGowan E, Sanders S, Iwatsubo T, et al. Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 1999;6:231-44
14. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: Lack of association with amyloid deposits. Behavior Genetics 1999;29:177-85
15. Arendash GW, King DL, Gordon MN, et al. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 2001;891:42-53
16. Sw transgenic mice develop age-related Aβ deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropath Exp Neurol 1997;56:965-73
17. Irizarry MC, Soriano F, McNamara M, et al. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997;17:7053-59
18. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999;96:3228-33
19. Gordon MN, King DL, Diamond DM, et al. Correlation between cognitive deficits and A beta deposits in transgenic APP+PS1 mice. Neurobiol Aging 2001;22:377-85
20. Puolivali J, Wang J, Heikkinen T, et al. Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 2002;9:339-47
21. Takeuchi A, Irizarry MC, Duff K, et al. Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein swedish mutant is not associated with global neuronal loss. Am J Pathol 2000;157:331-39
22. Chui DH, Tanahashi H, Ozawa K, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nature Med 1999;5:560-64
23. Sadowski M, Wen PH. Elder GA, Robakis NK, Wisniewski T. Effect of the presenilin 1 P117L FAD linked mutation on hippocampal morphology transgenic mice [abstract]. J Neuropathol Exp Neurol 2001;60:543
24. Eichenbaum H. Hippocampus: Mapping or memory? Curr Biol 2000;10:R785-R787
25. West MJ. New stereological methods for counting neurons. Neurobiol Aging 1993;14:275-85
26. West MJ, Slomianka L, Gundersen HJG. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anatomical Record 1991;231:482-97
27. West MJ, Kawas CH, Stewart WF, Troncoso JC. Neuronal loss in the hippocampus of individuals in early and advanced stages of Alzheimer's disease. Neurobiol Aging 2002;23:S333
28. West MJ, Kawas CH, Martin LJ, Troncoso JC. The CA1 region of the human hippocampus is a hot spot in Alzheimer's disease. Molecular and Cellular Gerontology 2000;908:255-59
29. Bobinski M, De Leon MJ, Tarnawski M, et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res 1998;805:267-69
30. Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996;383:710-13
31. Kluger A, Gianutsos JG, Golomb J, Ferris SH, Reisberg B. Motor/psychomotor dysfunction in normal aging, mild cognitive decline, and early Alzheimer's disease: Diagnostic and differential diagnostic features. Internat Psychogeriat 1997;1:28-39
32. Rosengarten H, Quartermain D. The effect of chronic treatment with typical and atypical antipsychotics on working memory and jaw movements in three- and eighteen-month-old rats. Prog Neuropsychopharmacology Biological Psychiatry 2002;26:1047-54
33. Feeney D, Gonzalez A, Law W. Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-57
34. Stone EA, Lin Y, Suckow RF, Quartermain D. Stress-induced subsensitivity to modafinil and its prevention by corticosteroids. Pharmacol Biochem Behav 2002;73:971-78
35. Olton DS, Samuelson R. Remembrance of places passed: spatial memory in rats. J Exp Psychol Animal Behav Proc 1976;2:97-116
36. Roullet P, Bozec G, Carton N. Detection of object orientation and spatial changes by mice: Importance of local views. Physiol Behav 1998;64:203-7
37. Ammassari-Teule M, Caprioli A. Spatial learning and memory, maze running strategies and cholinergic mechanisms in two inbred strains of mice. Behav Brain Res 1985;17:9-16
38. Paban V, Soumireu-Mourat B, Alescio-Lautier B. Behavioral effects of arginine(8)-vasopressin in the Hebb-Williams maze. Behav Brain Res 2003;141:1-9
39. Ando S, Kobayashi S, Waki H, et al. Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. J Neurosci Res 2002;70:519-27
40. Kobayashi S, Ohashi Y, Ando S. Effects of enriched environments with different durations and starting times on learning capacity during aging in rats assessed by a refined procedure of the Hebb-Williams maze task. J Neurosci Res 2002;70:340-46
41. Hoplight BJ, Sherman GF, Hyde LA, Denenberg VH. Effects of neocortical ectopias and environmental enrichment on Hebb-Williams maze learning in BXSB mice. Neurobiol Learn Mem 2001;76:33-45
42. Hsiao KK, Borchelt DR, Olson K, et al. Age-related cns disorder and early death in transgenic Fvb/N mice overexpressing alzheimer amyloid precursor proteins. Neuron 1995;15:1203-18
43. Iadecola C, Nakai M, Mraovitch S, Ruggiero DA, Tucker LW, Reis DJ. Global increase in cerebral metabolism and blood-flow produced by focal electrical-stimulation of dorsal medullary reticular-formation in rat. Brain Res 1983;272:101-14
44. Iadecola C, Xu XH. Nitro-L-arginine attenuates hypercapnic cerebrovasodilation without affecting cerebral metabolism. Am J Physiol 1994;266:R518-R525
45. Hof PR, Young WG, Bloom FE, Belichenko PV, Celio MR. Comparative cytoarchitectonic atlas of the C57BL/6 and 129/SV mouse brains. Amsterdam, The Netherlands: Elsevier Science B.V., 2000
46. Sharp FR, Kilduff TS, Bzorgchami S, Heller HC, Ryan AF. The relationship of local cerebral glucose-utilization to optical-density ratios. Brain Res 1983;263:97-103
47. Crossman AR, Mitchell IJ, Sambrook MA. Experimental hemiballismus - A [H-3] 2-deoxyglucose study in the monkey (Macaca-Fascicularis). J Physiol London 1984;353:121
48. Mitchell IJ, Crossman AR. In defense of optical-density ratios in 2-deoxyglucose autoradiography. Brain Res 1984;298:191-92
49. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J. Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 1998;57:674-83
50. Kim KS, Miller DL, Sapienza VJ, et al. Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Comm 1988;2:121-30
51. Wadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detection of Alzheimer's amyloid lesions in transgenic mice by magnetic resonance imaging. Magn Reson Med (in press)
52. Schmidtkastner R, Freund TF. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience 1991;40:599-636
53. West MJ, Gundersen HJG. Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 1990;296:1-22
54. Sadowski M, Wisniewski HM, Jakubowska-Sadowska K, Tarnawski M, Lazarewicz JW, Mossakowski MJ. Pattern of neuronal loss in the rat hippocampus following experimental cardiac arrest-induced ischemia. J Neurol Sci 1999;168:13-20
55. Gómez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 1997;41:17-24
56. Hyman BT, Gomez-Isla T, West H, et al. Clinical and neuropathological correlates of apolipoprotein E genotype in Alzheimer's disease - Window on molecular epidemiology. Ann NY Acad Sci 1996;777:158-65
57. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behavioral Neuroscience 1999;113:982-90
58. Moran PM, Higgins LS, Cordell B, Moser PC. Beta-App751 transgenic mice exhibit impaired learning. Neurobiol Aging 1994;15:S12
59. Sclan SG, Reisberg B. Functional Assessment Staging (FAST) in Alzheimer's disease: Reliability, validity and ordinality. Internat Psychogeriat 1992;4:55-69
60. Reisberg B, Sclan SG, Franssen E, et al. Clinical stages of normal aging and Alzheimers-disease - The gds staging system. Neurosci Res Comm 1993;13:S51-S54
61. Reisberg B, Finkel S, Overall J, et al. The Alzheimer's disease activities of daily living international scale (ADL-IS). International Psychogeriatrics 2001;13:163-81
62. Reisberg B, Franssen EH, Auer S, et al. Clinical course and the neglected half of Alzheimer's disease. Neurobiol Aging 1996;17:5
63. Calhoun ME, Wiederhold KH, Abramowski D, et al. Neuron loss in APP transgenic mice. Nature 1998;396:755-56
64. Gundersen HJG, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis - Review article. APMIS 1988;96:379-94
65. Gundersen HJG, Bagger P, Bendtsen TF, et al. The new stereological tools - Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988;96:857-81
66. Lu B. Pro-region of neurotrophins: Role in synaptic modulation. Neuron 2003;39:735-38
67. Marc RE, Jones BW, Watt CB, Strettoi E. Neural remodeling in retinal degeneration. Progress in Retinal and Eye Research 2003;22:607-55
68. Esaki T, Suzuki H, Cook M, et al. Functional activation of cerebral metabolism in mice with mutated thyroid hormone nuclear receptors. Endocrinology 2003;144:4117-22
69. Mattson MP, Liu D. Energetics and oxidative stress in synaptic plasticity and neurodegenerative disorders. Neuromolecular Medicine 2002;2:215-31
70. Browne SE, Lin L, Mattsson A, Georgievska B, Isacson O. Selective antibody-induced cholinergic cell and synapse loss produce sustained hippocampal and cortical hypometabolism with correlated cognitive deficits. Exp Neurol 2001;170:36-47
71. Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Phil Trans R Soc Lond B Biol Sci 1999;354:1155-63
72. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radical Res 2002;36:1307-13
73. Hensley K, Butterfield DA, Hall N, et al. Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Ann NY Acad Sci 1996;786:120-34
74. Bigl M, Apelt J, Eschrich K, Schliebs R. Cortical glucose metabolism is altered in aged transgenic Tg2576 mice that demonstrate Alzheimer plaque pathology. J Neural Transm 2003;110:77-94
75. Abe K, Kimura H. Amyloid beta toxicity consists of a Ca2+-independent early phase and a Ca2+-dependent late phase. J Neurochem 1996;67:2074-78
76. Apelt J, Kumar A, Schliebs R. Impairment of cholinergic neurotransmission in adult and aged transgenic Tg2576 mouse brain expressing the Swedish mutation of human beta-amyloid precursor protein. Brain Res 2002;953:17-30
77. Ye CP, Selkoe DJ, Hartley DM. Protofibrils of amyloid beta-protein inhibit specific K+ currents in neocortical cultures. Neurobiol Dis 2003;13:177-90
78. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996;16:5795-811
79. Wong TP, Debeir T, Duff K, Cuello AC. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci 1999;19:2706-16
80. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-91
81. Higgins LS, Holtzman DM, Rabin J, Mobley WC, Cordell B. Transgenic mouse-brain histopathology resembles early Alzheimers-Disease. Ann Neurol 1994;35:598-607